<?xml version="1.0" encoding="UTF-8"?>
<p>Clinical trials are required in particular for confirming safety and efficacy for COVID-19 RNA synthesis inhibitors (like 3TC, TDF), remdesivir, neuraminidase inhibitors, peptide (EK1), anti-inflammatory drugs, and arbidol [
 <xref rid="B52-ijms-21-05145" ref-type="bibr">52</xref>]. In vitro and in vivo studies have shown anti-CoV activities of molecules that affect the S1 protein as either S-protein inhibitors, S cleavage inhibitors and RBDâ€“ACE2 blockers. In this regard, phase III trials are ongoing with remdesivir, lopinavir, oseltamivir, darunavir, the HIV (Human Immunodeficiency Virus) protease inhibitor ASC09F, ritonavir, and cobicistat [
 <xref rid="B52-ijms-21-05145" ref-type="bibr">52</xref>]. There is, so far, a lack of supportive evidence of safety and efficacy of Chinese traditional medicine products already employed to treat other CoV infections [
 <xref rid="B16-ijms-21-05145" ref-type="bibr">16</xref>,
 <xref rid="B53-ijms-21-05145" ref-type="bibr">53</xref>].
</p>
